Levalbuterol Solution
Product Images NDC 0093-4145

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Levalbuterol (NDC 0093-4145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure of Levalbuterol depicted as a molecular diagram showing its hydroxyl groups, amine group, and associated hydrochloride (HCl) component.*

FDA Label Image

Figure E.1 (Image 10)

An instructional diagram showing parts of a respiratory inhalation device for Levalbuterol solution. The image labels the mouthpiece and the reservoir of the inhalation apparatus, illustrating how the components fit together for use.*

FDA Label Image

Figure E.2 (Image 11)

An instructional diagram showing a respiratory inhalation setup with a labeled face mask and reservoir. The face mask is depicted as covering the nose and mouth, connected to a reservoir device on the right.*

FDA Label Image

Figure F (Image 12)

An illustration showing a compressor device labeled 'COMPRESSOR' with a control knob and a digital display or indicator. A tube labeled 'NEBULIZER TUBING' is connected to the compressor, illustrating part of a nebulizer setup for respiratory inhalation therapy.*

FDA Label Image

Figure G.1 (Image 13)

An instructional illustration showing the correct positioning of a mouthpiece and reservoir for a respiratory inhalation device, likely for Levalbuterol solution. The graphic depicts a side profile of a person's face with the mouthpiece placed in the mouth and the reservoir held below, indicating the proper use of the inhalation device.*

FDA Label Image

Figure G.2 (Image 14)

An instructional illustration showing a respiratory solution inhalation device with a labeled face mask and reservoir. The image highlights components to assist in proper use of the inhalation solution device.*

FDA Label Image

Levalbuterol Inhalation Solution Usp 0.31 mg/3 mL 24 Unit-dose Vials Carton, Part 1 Of 2 (Image 15)

Levalbuterol Inhalation Solution USP 0.31 mg/3 mL in sterile unit-dose vials for respiratory inhalation, not for injection. The label shows storage instructions to protect from light and heat, and packaging details of 6 pouches containing five 3 mL vials each (30 unit-dose vials). The product is labeled by Teva Pharmaceuticals USA, Inc., with NDC 0093-4145-56.*

FDA Label Image

Levalbuterol Inhalation Solution Usp 0.31 mg/3 mL 24 Unit-dose Vials Carton, Part 2 Of 2 (Image 16)

Levalbuterol Inhalation Solution USP 0.31 mg/3 mL packaging label for 6 pouches of five 3 mL unit-dose vials (30 vials total). Manufactured in England by Norton Healthcare Limited for Teva Pharmaceuticals USA, Inc. The label includes the NDC 0093-4145-56 and states the solution is for oral inhalation only, not for injection. The Teva logo is displayed on a green background.*

FDA Label Image

Levalbuterol Inhalation Solution Usp 0.63 mg/3 mL 24 Unit-dose Vials Carton, Part 1 Of 2 (Image 17)

Packaging label for Levalbuterol Inhalation Solution USP 0.63 mg/3 mL by Teva Pharmaceuticals USA, Inc. The label indicates sterile unit-dose vials for oral inhalation only, with 6 pouches of five 3 mL vials each (30 unit-dose vials total). It includes storage instructions and a note to pharmacists about patient information and dosage.*

FDA Label Image

Levalbuterol Inhalation Solution Usp 0.63 mg/3 mL 24 Unit-dose Vials Carton, Part 2 Fo 2 (Image 18)

Packaging label for Levalbuterol Inhalation Solution USP 0.63 mg/3 mL by Teva Pharmaceuticals USA, Inc. The box contains 6 pouches of five 3 mL unit-dose vials (30 vials total). The label includes product and manufacturer information, as well as dosing form and route (respiratory inhalation).*

FDA Label Image

Levalbuterol Inhalation Solution Usp 1.25 mg/3 mL 24 Unit-dose Vials Carton, Part 1 Of 2 (Image 19)

Carton label for Levalbuterol Inhalation Solution USP 1.25 mg/3 mL by Teva Pharmaceuticals USA, Inc. The label states it contains sterile unit-dose vials for oral inhalation only, not for injection. Packaging includes 6 pouches of five 3 mL vials each (30 unit-dose vials). Instructions highlight protecting the product from light and heat and proper storage guidelines.*

FDA Label Image

Image 2

A line graph showing mean change in FEV1 (%) over 8 hours for four groups: Lev 1.25 mg, Lev 0.63 mg, Rac 2.5 mg, and Placebo (PBO). The y-axis represents mean change in FEV1 (%) from -5 to 45%, and the x-axis represents time in hours from 0 to 8. Data points indicate participants in each group, with Lev 1.25 mg showing the highest increase early on, followed by Lev 0.63 mg, Rac 2.5 mg, and PBO showing the lowest change.*

FDA Label Image

Levalbuterol Inhalation Solution Usp 1.25 mg/3 mL 24 Unit-dose Vials Carton, Part 2 Of 2 (Image 20)

The packaging label for Levalbuterol Inhalation Solution USP, 1.25 mg/3 mL, shows a box containing 6 pouches of five 3 mL unit-dose vials (30 total). It is labeled for respiratory inhalation only, manufactured for Teva Pharmaceuticals USA, Inc., and includes the NDC 0093-4148-56. The brand Steri-Neb is mentioned for the sterile unit-dose vials.*

FDA Label Image

Image 3

A line graph depicting mean change in FEV1 (%) over 8 hours for different treatment groups: Levalbuterol 1.25 mg, 0.63 mg, Racemic albuterol 2.5 mg, and placebo. The graph shows peak changes around 1 hour with decreases thereafter, comparing the respiratory inhalation effects of these doses.*

FDA Label Image

Image 4

A line graph illustrating the mean change in FEV1 (%) over time (hours) following administration of different doses of Levalbuterol (0.31 mg and 0.63 mg), Racemic mixtures (1.25 mg and 2.5 mg), and placebo (Pbo). The graph compares respiratory function over a 4-hour period post-dose in multiple subject groups, showing mean FEV1 changes and variation among the treatments.*

FDA Label Image

Image 5

A line graph depicting the mean change in FEV1 (%) over time (hours) for different doses of Levalbuterol (.31 mg and .63 mg), Racemic Albuterol (1.25 mg and 2.5 mg), and placebo. The graph shows response curves up to 4 hours post-dose, illustrating respiratory function changes for each treatment group.*

FDA Label Image

Image 6

An instructional illustration showing a vial with a twist-off tab. Labels indicate the 'twist off tab' areas on both sides of the vial's top, with a shaded area representing the twist-off tab portion of the vial.*

FDA Label Image

Image 7

An illustration showing the top portion of a sachet or pouch with a tear-at-seam feature marked by an arrow, indicating where to open the package. No product branding or additional text is visible.*

FDA Label Image

Image 8

An instructional illustration showing a hand holding a vial or ampule with an arrow indicating the motion to snap or break the top off the vial, likely demonstrating preparation steps for inhalation solution administration.*

FDA Label Image

Image 9

An instructional illustration showing a hand inserting a vial labeled 'VIAL' into a device labeled 'RESERVOIR.' The image appears to guide the preparation or assembly of a respiratory inhalation solution device.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.